We would like to inform you that, the Board of Directors of the Company at their meeting held today i.e. 03rd November, 2025 has, inter alia considered and approved Unaudited Financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts less than Nifty Microcap 250 and 5.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Colinz Laboratories approved unaudited (Ind AS) results for Q2 and H1 FY26 ended 30 September 2025. Revenue from operations dropped to Rs. 138.80 lakhs in Q2 FY26 from Rs. 186.31 lakhs in Q2 FY25, a fall of about 25.5% year-on-year. Half-year revenue stood at Rs. 295.41 lakhs versus Rs. 360.97 lakhs in H1 FY25, down roughly 18%. Profit after tax was Rs. 14.05 lakhs in Q2 (vs Rs. 15.57 lakhs) and Rs. 25.97 lakhs in H1 (vs Rs. 29.29 lakhs), translating to an EPS of Rs. 0.56 and Rs. 1.03 respectively. Statutory auditor Vora & Associates issued an unqualified limited review report with no qualifications. The company, engaged in pharmaceutical formulations, remains virtually debt-free with cash and bank balances of about Rs. 742 lakhs and positive operating cash flow of Rs. 166.19 lakhs for the half year.
The double-digit revenue decline may weigh on near-term investor sentiment, but stable margins, an unqualified audit report, and a strong net-cash balance sheet limit downside risk for shareholders.